Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 68477 | 7.99 |
09:34 ET | 34019 | 7.95 |
09:36 ET | 41745 | 7.9471 |
09:38 ET | 17227 | 7.95 |
09:39 ET | 5159 | 8.0297 |
09:41 ET | 10701 | 8.08 |
09:43 ET | 14363 | 8.12 |
09:45 ET | 35405 | 8.19 |
09:48 ET | 26692 | 8.3 |
09:50 ET | 36615 | 8.2673 |
09:52 ET | 45069 | 8.46 |
09:54 ET | 36206 | 8.3 |
09:56 ET | 16975 | 8.11 |
09:57 ET | 31690 | 8 |
09:59 ET | 9566 | 8.06 |
10:01 ET | 7490 | 8.04 |
10:03 ET | 5665 | 8.06 |
10:06 ET | 4478 | 8.08 |
10:08 ET | 21701 | 8.04 |
10:10 ET | 30111 | 7.915 |
10:12 ET | 15221 | 8.02 |
10:14 ET | 11733 | 7.945 |
10:15 ET | 17928 | 8 |
10:17 ET | 8614 | 8.02 |
10:19 ET | 9077 | 8.13 |
10:21 ET | 19917 | 8.2398 |
10:24 ET | 19242 | 8.24 |
10:26 ET | 10112 | 8.2 |
10:28 ET | 16439 | 8.2 |
10:30 ET | 5348 | 8.13 |
10:32 ET | 15332 | 8.14 |
10:33 ET | 13777 | 8.17 |
10:35 ET | 21107 | 8.21 |
10:37 ET | 5529 | 8.13 |
10:39 ET | 5767 | 8.21 |
10:42 ET | 17128 | 8.13 |
10:44 ET | 3185 | 8.13 |
10:46 ET | 5702 | 8.12 |
10:48 ET | 50939 | 8 |
10:50 ET | 22380 | 8.046 |
10:51 ET | 1000 | 8.005 |
10:53 ET | 3476 | 7.99 |
10:55 ET | 7964 | 8 |
10:57 ET | 46503 | 7.895 |
11:00 ET | 10546 | 7.85 |
11:02 ET | 7226 | 7.87 |
11:04 ET | 11124 | 7.8579 |
11:06 ET | 40010 | 7.845 |
11:08 ET | 7274 | 7.82 |
11:09 ET | 10194 | 7.81 |
11:11 ET | 14253 | 7.825 |
11:13 ET | 8261 | 7.77 |
11:15 ET | 6443 | 7.795 |
11:18 ET | 1500 | 7.795 |
11:20 ET | 5172 | 7.78 |
11:22 ET | 3596 | 7.795 |
11:24 ET | 9082 | 7.89 |
11:26 ET | 3183 | 7.9 |
11:27 ET | 5671 | 7.84 |
11:29 ET | 8996 | 7.88 |
11:31 ET | 24074 | 7.815 |
11:33 ET | 11197 | 7.82 |
11:36 ET | 13807 | 7.88 |
11:38 ET | 11615 | 7.845 |
11:40 ET | 5539 | 7.8 |
11:42 ET | 14399 | 7.9076 |
11:44 ET | 9354 | 7.86 |
11:45 ET | 5312 | 7.87 |
11:47 ET | 9775 | 7.905 |
11:49 ET | 57582 | 7.975 |
11:51 ET | 17335 | 7.94 |
11:54 ET | 51703 | 7.805 |
11:56 ET | 27384 | 7.79 |
11:58 ET | 7710 | 7.7898 |
12:00 ET | 7734 | 7.8 |
12:02 ET | 12173 | 7.78 |
12:03 ET | 3300 | 7.82 |
12:05 ET | 2138 | 7.81 |
12:07 ET | 5709 | 7.8198 |
12:09 ET | 8036 | 7.87 |
12:12 ET | 5559 | 7.82 |
12:14 ET | 5600 | 7.81 |
12:16 ET | 1885 | 7.79 |
12:18 ET | 3381 | 7.79 |
12:20 ET | 1468 | 7.78 |
12:21 ET | 3318 | 7.83 |
12:23 ET | 2805 | 7.85 |
12:25 ET | 7595 | 7.85 |
12:27 ET | 2063 | 7.86 |
12:30 ET | 7107 | 7.81 |
12:32 ET | 24825 | 7.76 |
12:34 ET | 12429 | 7.77 |
12:36 ET | 1500 | 7.79 |
12:38 ET | 13010 | 7.8 |
12:39 ET | 4095 | 7.82 |
12:41 ET | 900 | 7.835 |
12:43 ET | 2396 | 7.845 |
12:45 ET | 3532 | 7.85 |
12:48 ET | 4287 | 7.805 |
12:50 ET | 11820 | 7.78 |
12:52 ET | 7023 | 7.72 |
12:54 ET | 3947 | 7.735 |
12:56 ET | 1520 | 7.736 |
12:57 ET | 1946 | 7.738 |
12:59 ET | 21270 | 7.665 |
01:01 ET | 30719 | 7.75 |
01:03 ET | 4574 | 7.72 |
01:06 ET | 4300 | 7.75 |
01:08 ET | 3119 | 7.735 |
01:10 ET | 8814 | 7.71 |
01:12 ET | 5177 | 7.71 |
01:14 ET | 1850 | 7.715 |
01:15 ET | 4426 | 7.7 |
01:17 ET | 2753 | 7.705 |
01:19 ET | 1096 | 7.715 |
01:21 ET | 1256 | 7.74 |
01:24 ET | 4824 | 7.705 |
01:26 ET | 3128 | 7.7001 |
01:28 ET | 2628 | 7.69 |
01:30 ET | 6088 | 7.685 |
01:32 ET | 2363 | 7.72 |
01:33 ET | 4059 | 7.74 |
01:35 ET | 1400 | 7.716 |
01:37 ET | 4377 | 7.725 |
01:39 ET | 1101 | 7.72 |
01:42 ET | 2520 | 7.7105 |
01:44 ET | 5280 | 7.7299 |
01:46 ET | 28597 | 7.67 |
01:48 ET | 5052 | 7.67 |
01:50 ET | 8795 | 7.69 |
01:51 ET | 3304 | 7.695 |
01:53 ET | 2579 | 7.68 |
01:55 ET | 2104 | 7.69 |
01:57 ET | 12851 | 7.675 |
02:00 ET | 18248 | 7.68 |
02:02 ET | 6361 | 7.67 |
02:04 ET | 2707 | 7.705 |
02:06 ET | 3312 | 7.69 |
02:08 ET | 9180 | 7.74 |
02:09 ET | 3547 | 7.75 |
02:11 ET | 5563 | 7.75 |
02:13 ET | 19621 | 7.69 |
02:15 ET | 4164 | 7.72 |
02:18 ET | 9698 | 7.715 |
02:20 ET | 11617 | 7.715 |
02:22 ET | 11919 | 7.76 |
02:24 ET | 21531 | 7.8 |
02:26 ET | 5935 | 7.81 |
02:27 ET | 11230 | 7.82 |
02:29 ET | 13049 | 7.79 |
02:31 ET | 7084 | 7.775 |
02:33 ET | 5362 | 7.75 |
02:36 ET | 3243 | 7.75 |
02:38 ET | 5249 | 7.77 |
02:40 ET | 6003 | 7.775 |
02:42 ET | 7303 | 7.77 |
02:44 ET | 2000 | 7.79 |
02:45 ET | 6201 | 7.82 |
02:47 ET | 9854 | 7.815 |
02:49 ET | 4568 | 7.8 |
02:51 ET | 4821 | 7.78 |
02:54 ET | 4396 | 7.78 |
02:56 ET | 40284 | 7.7 |
02:58 ET | 4925 | 7.68 |
03:00 ET | 5200 | 7.675 |
03:02 ET | 4597 | 7.72 |
03:03 ET | 3806 | 7.77 |
03:05 ET | 6119 | 7.785 |
03:07 ET | 5166 | 7.79 |
03:09 ET | 9093 | 7.81 |
03:12 ET | 6163 | 7.83 |
03:14 ET | 7876 | 7.81 |
03:16 ET | 12598 | 7.86 |
03:18 ET | 17783 | 7.85 |
03:20 ET | 14644 | 7.875 |
03:21 ET | 8749 | 7.88 |
03:23 ET | 9442 | 7.85 |
03:25 ET | 8593 | 7.805 |
03:27 ET | 8996 | 7.8 |
03:30 ET | 11238 | 7.7702 |
03:32 ET | 30611 | 7.78 |
03:34 ET | 13705 | 7.8 |
03:36 ET | 16146 | 7.79 |
03:38 ET | 10237 | 7.77 |
03:39 ET | 43896 | 7.805 |
03:41 ET | 21211 | 7.775 |
03:43 ET | 4900 | 7.8 |
03:45 ET | 9474 | 7.795 |
03:48 ET | 21629 | 7.785 |
03:50 ET | 21031 | 7.78 |
03:52 ET | 17763 | 7.81 |
03:54 ET | 26148 | 7.8 |
03:56 ET | 42583 | 7.75 |
03:57 ET | 46513 | 7.735 |
03:59 ET | 104086 | 7.72 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.1B | -46.6x | --- |
Madrigal Pharmaceuticals Inc | 5.2B | -10.6x | --- |
BridgeBio Pharma Inc | 5.1B | -8.4x | --- |
Cytokinetics Inc | 5.5B | -9.8x | --- |
Nuvalent Inc | 4.5B | -32.9x | --- |
Krystal Biotech Inc | 4.6B | 87.4x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.6B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.95 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -46.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.